Tec family kinases in inflammation and disease

International Reviews of Immunology

Volumn 31, Issue 2, 2012, Pages 87-103

  Horwood, Nicole J ^a   Urbaniak, Ania M ^a   Danks, Lynett ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Arthritis; Btk; Inflammation; Tyrosine kinase

Indexed keywords

AVL 292; BONE MARROW KINASE; BRUTON TYROSINE KINASE; DASATINIB; FC RECEPTOR IIB; FOSTAMATINIB; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBRUTINIB; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TEC PROTEIN; TOFACITINIB; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL INTERACTION; CELL MATURATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CREATININE BLOOD LEVEL; CROHN DISEASE; CYTOKINE PRODUCTION; DENDRITIC CELL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; ENTERITIS; ENZYME ACTIVATION; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GRAFT REJECTION; HEADACHE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LIVER FUNCTION TEST; MACROPHAGE ACTIVATION; MONOCYTE; MONOTHERAPY; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OSTEOCLAST; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN INFECTION; SYNOVITIS; TH1 TH2 BALANCE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; ENZYME INHIBITORS; HUMANS; INFLAMMATION; MICE; MYELOID CELLS; PROTEIN-TYROSINE KINASES;

EID: 84860435487     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2012.670334     Document Type: Review

References (139)

1. Danks L,Workman S,Webster D, Horwood NJ. Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts. J BoneMiner Res. 2011;26(1):182-192.
2. Doyle SL, Jefferies CA, Feighery C, O'Neill LA. Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase. J Biol Chem. 2007;282(51):36953-36960.
3. HorwoodNJ,Mahon T,McDaid JP, et al. Bruton's tyrosine kinase is required for lipopolysaccharideinduced tumor necrosis factor alpha production. J ExpMed. 2003;197(12):1603-1611. (Pubitemid 36745336)
4. Horwood NJ, Page TH, McDaid JP, et al. Bruton's tyrosine kinase is required for TLR2 and TLR4- induced TNF, but not IL-6, production. J Immunol. 2006;176(6):3635-3641. (Pubitemid 43364011)
5. Jefferies CA, O'Neill LA. Bruton's tyrosine kinase (Btk)-the critical tyrosine kinase in LPS signallingč Immunol Lett. 2004;92(1-2):15-22. (Pubitemid 38470045)
6. Palmer CD, Mutch BE, Page TH, Horwood NJ, Foxwell BM. Bmx regulates LPS-induced IL-6 and VEGF production via mRNA stability in rheumatoid synovial fibroblasts. Biochem Biophys Res Commun. 2008;370(4):599-602.
7. Palmer CD,MutchBE,Workman S,McDaid JP,HorwoodNJ, FoxwellBM. Bmx tyrosine kinase regulates TLR4-induced IL-6 production in humanmacrophages independently of p38 MAPK andNFkappaB activity. Blood. 2008;111(4):1781-1788. (Pubitemid 351451482)
8. Jumaa H, Hendriks RW, Reth M. B cell signaling and tumorigenesis. Annu Rev Immunol. 2005;23:415-445. (Pubitemid 40563176)
9. Koprulu AD, Ellmeier W. The role of Tec family kinases in mononuclear phagocytes. Crit Rev Immunol. 2009;29(4):317-333.
10. Readinger JA, Mueller KL, Venegas AM, Horai R, Schwartzberg PL. Tec kinases regulate Tlymphocyte development and function: new insights into the roles of Itk and Rlk/Txk. Immunol Rev 2009;228(1):93-114.
11. Feldmann M,Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev. 2008;223:7-19. (Pubitemid 351986171)
12. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8(10):776-787.
13. Mantovani A. B cells andmacrophages in cancer: yin and yang. NatMed. 2011;17(3):285-286.
14. Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem. 2007;76:447-480.
15. Beaty CD, Franklin TL, Uehara Y, Wilson CB. Lipopolysaccharide-induced cytokine production in human monocytes: role of tyrosine phosphorylation in transmembrane signal transduction. Eur J Immunol. 1994;24(6):1278-1284. (Pubitemid 24169507)
16. Weinstein SL, Gold MR, DeFranco AL. Bacterial lipopolysaccharide stimulates protein tyrosine phosphorylation inmacrophages. Proc Nat Acad Sci USA. 1991;88(10):4148-4152. (Pubitemid 21914496)
17. Arditi M, Zhou J, Torres M, Durden DL, Stins M, Kim KS. Lipopolysaccharide stimulates the tyrosine phosphorylation of mitogen-activated protein kinases p 44, p 42, and p 41 in vascular endothelial cells in a soluble CD14-dependent manner: role of protein tyrosine phosphorylation in lipopolysaccharide-induced stimulation of endothelial cells. J Immunol. 1995;155(8):3994-4003.
18. Dong Z, Qi X, Xie K, Fidler IJ. Protein tyrosine kinase inhibitors decrease induction of nitric oxide synthase activity in lipopolysaccharide- responsive and lipopolysaccharide-nonresponsivemurine macrophages. J Immunol. 1993;151(5):2717-2724. (Pubitemid 23264523)
19. Mander T, Hill S, Hughes A, et al. Differential effects on TNF alpha production by pharmacological agents with varyingmolecular sites of action. Int J Immunopharmacol. 1997;19(8):451-462. (Pubitemid 28161131)
20. Lee HS, Moon C, Lee HW, Park EM, Cho MS, Kang JL. Src tyrosine kinases mediate activations of NF-kappaB and integrin signal during lipopolysaccharide- induced acute lung injury. J Immunol. 2007;179(10):7001-7011.
21. Meng F, LowellCA. Lipopolysaccharide (LPS)-inducedmacrophage activation and signal transduction in the absence of Src-family kinases Hck, Fgr, and Lyn. J ExpMed. 1997;185(9):1661-1670. (Pubitemid 27203262)
22. Smolinska MJ, Horwood NJ, Page TH, Smallie T, Foxwell BM. Chemical inhibition of Src family kinases affects major LPS-activated pathways in primary human macrophages. Mol Immunol. 2008;45(4):990-1000. (Pubitemid 350017845)
23. SmolinskaMJ, Page TH,Urbaniak AM,Mutch BE,Horwood NJ.Hck tyrosine kinase regulates TLR4- induced TNF and IL-6 production via AP-1. J Immunol. 2011;187(11):6043-6051.
24. Cha HS, Boyle DL, Inoue T, et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol ExpTher. 2006;317(2):571-578.
25. Mocsai A, Humphrey MB, Van Ziffle JA, et al.Theimmunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcR gamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Nat Acad Sci USA. 2004;101(16):6158-6163. (Pubitemid 38520544)
26. Wicker LS, Scher I. X-linkedimmune deficiency (xid) of CBA/Nmice. Curr TopMicrobiolImmunol. 1986;124:87-101.
27. Rawlings DJ, Witte ON. Bruton's tyrosine kinase is a key regulator in B-cell development. Immunol Rev. 1994;138:105-119. (Pubitemid 24147418)
28. Vetrie D, Vorechovsky I, Sideras P, et al.The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361(6409):226-233. (Pubitemid 23034471)
29. Reth M, Wienands J. Initiation and processing of signals fromthe B cell antigen receptor. Annu Rev Immunol. 1997;15:453-479. (Pubitemid 27169289)
30. Kurosaki T. Regulation of BCR signaling.Mol Immunol. 2011;48(11):1287- 1291.
31. Fluckiger AC, Li Z, Kato RM, et al. Btk/Tec kinases regulate sustained increases in intracellularCa2+ following B-cell receptor activation. EMBO J. 1998;17(7):1973-1985. (Pubitemid 28154527)
32. Mohamed AJ, Yu L, Backesjo CM, et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228(1):58-73.
33. Ishiai M, Kurosaki M, Pappu R, et al. BLNKrequired for coupling Syk to PLC gamma 2 and Rac1-JNK in B cells. Immunity. 1999;10(1):117-125. (Pubitemid 29077389)
34. IshiaiM,Sugawara H,KurosakiM,Kurosaki T.Cutting edge: association ofphospholipaseC-gamma 2 Src homology 2 domains with BLNK is critical for B cell antigen receptor signaling. J Immunol. 1999;163(4):1746-1749. (Pubitemid 29382170)
35. Hemmings BA. Akt signaling: linking membrane events to life and death decisions. Science. 1997;275(5300):628-630. (Pubitemid 27061321)
36. Okada T, Maeda A, Iwamatsu A, Gotoh K, Kurosaki T. BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity. 2000;13(6):817-827. (Pubitemid 32041804)
37. Forssell J, Nilsson A, Sideras P. Reduced formation of phosphatidic acid upon B-cell receptor triggering of mouse B-lymphocytes lacking Bruton's tyrosine kinase. Scand J Immunol. 2000;52(1):30-38. (Pubitemid 30435982)
38. Suzuki H,Matsuda S, Terauchi Y, et al. PI3K and Btk differentially regulate B cell antigen receptormediated signal transduction. Nat Immunol. 2003;4(3):280-286. (Pubitemid 36322139)
39. Fukuda M, Kojima T, Kabayama H, Mikoshiba K. Mutation of the pleckstrin homology domain of Bruton's tyrosine kinase in immunodeficiency impaired inositol 1,3,4,5-tetrakisphosphate binding capacity. J Biol Chem. 1996;271(48):30303-30306. (Pubitemid 26404025)
40. Marshall AJ, Niiro H, Yun TJ, Clark EA. Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase C gamma pathway. Immunol Rev. 2000;176:30-46.
41. Satterthwaite AB, Li Z, WitteON. Btk function in B cell development and response. SeminImmunol. 1998;10(4):309-316. (Pubitemid 28375306)
42. Takai T,Ono M,Hikida M,Ohmori H, Ravetch JV. Augmented humoral and anaphylactic responses in Fc gamma RII-deficientmice. Nature. 1996;379(6563):346-349. (Pubitemid 26033077)
43. OnoM, Bolland S, Tempst P, Ravetch JV. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature. 1996;383(6597):263-266. (Pubitemid 26317676)
44. Bolland S, Pearse RN, Kurosaki T, Ravetch JV. SHIPmodulates immune receptor responses by regulatingmembrane association of Btk. Immunity. 1998;8(4):509-516. (Pubitemid 28196804)
45. Blank MC, Stefanescu RN, Masuda E, et al. Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus. HumGenet. 2005;117(2-3):220-227. (Pubitemid 43136798)
46. CatalanD, Aravena O, Sabugo F, et al. B cells from rheumatoid arthritis patients showimportant alterations inthe expression ofCD86and Fc gammaRIIb,which aremodulated by anti-tumornecrosis factor therapy. Arthritis ResTher. 2010;12(2):R68.
47. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34-47.
48. Pearse RN,Kawabe T,Bolland S,GuinamardR,Kurosaki T,Ravetch JV. SHIP recruitment attenuates Fc gamma RIIB-induced B cell apoptosis. Immunity. 1999;10(6):753-760. (Pubitemid 29302928)
49. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Nat Acad Sci USA. 1992;89(14):6550-6554.
50. Mizuno T, Rothstein TL. Cutting edge: CD40 engagement eliminates the need for Bruton's tyrosine kinase in B cell receptor signaling for NF-kappa B. J Immunol. 2003;170(6):2806-2810. (Pubitemid 36302149)
51. Brunner C, Kreth HW, Ochs HD, Schuster V. Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia. J Clin Immunol. 2002;22(4):244-251. (Pubitemid 34774988)
52. Ying H, Li Z, Yang L, Zhang J. Syk mediates BCR- and CD40-signaling integration during B cell activation. Immunobiology. 2011;216(5):566-570.
53. Tamagnone L, Lahtinen I,Mustonen T, et al. BMX, a novel nonreceptor tyrosine kinase gene of the BTK/ITK/TEC/TXK family located in chromosome Xp22.2. Oncogene. 1994;9(12):3683-3688.
54. Saharinen P, Ekman N, Sarvas K, Parker P, Alitalo K, Silvennoinen O. The Bmx tyrosine kinase induces activation of the Stat signaling pathway, which is specifically inhibited by protein kinase C delta. Blood. 1997;90(11):4341-4353. (Pubitemid 27508440)
55. TomlinsonMG,Kurosaki T, Berson AE, Fujii GH, Johnston JA, Bolen JB. Reconstitution ofBtk signaling by the atypical tec family tyrosine kinases Bmx and Txk. J Biol Chem. 1999;274(19):13577-13585.
56. Rajantie I, Ekman N, Iljin K, et al. Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium. Mol Cell Biol. 2001;21(14):4647-4655. (Pubitemid 32588247)
57. Ellmeier W, Jung S, Sunshine MJ, et al. Severe B cell deficiency in mice lacking the tec kinase family members Tec and Btk. J ExpMed. 2000;192(11):1611-1624.
58. Kitanaka A,Mano H, Conley ME,Campana D. Expression and activation of the nonreceptor tyrosine kinase Tec in human B cells. Blood. 1998;91(3):940-948. (Pubitemid 28078297)
59. ShinoharaM, Koga T, Okamoto K, et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell. 2008;132(5):794-806. (Pubitemid 351312796)
60. Horowitz MC, Bothwell AL, Hesslein DG, Pflugh DL, Schatz DG. B cells and osteoblast and osteoclast development. Immunol Rev. 2005;208:141-153. (Pubitemid 41746390)
61. Horowitz MC, Fretz JA, Lorenzo JA.HowB cells influence bone biology in health and disease. Bone. 2010;47(3):472-479.
62. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev. 2008;29(4):403-440. (Pubitemid 351831507)
63. Yun TJ, Chaudhary PM, Shu GL, et al. OPG/FDCR-1, a TNF receptor familymember, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol. 1998;161(11):6113-6121. (Pubitemid 28535982)
64. Perlot T, Penninger JM. Development and function of murine B cells lacking RANK. J Immunol. 2012;188(3):1201-1205.
65. Koga T, Inui M, Inoue K, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature. 2004;428(6984):758-763. (Pubitemid 38508286)
66. Lee SH, Kim T, Jeong D, KimN, Choi Y.The tec family tyrosine kinase Btk regulates RANKL-induced osteoclastmaturation. J Biol Chem. 2008;283(17):11526- 11534.
67. Barrow AD, Raynal N, Andersen TL, et al. OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest. 2011;121(9):3505-3516.
68. Gordon S. Themacrophage: past, present and future. Eur J Immunol. 2007;37(Suppl. 1):S9-S17.
69. Martinez FO, Gordon S, Locati M,Mantovani A. Transcriptional profiling of the humanmonocyteto- macrophage differentiation and polarization: newmolecules and patterns of gene expression. J Immunol. 2006;177(10):7303-7311. (Pubitemid 44715100)
70. Hume DA.Macrophages as APC and the dendritic cellmyth. J Immunol. 2008;181(9):5829-5835.
71. Sakuma C, Sato M, Takenouchi T, Chiba J, Kitani H. Critical roles of the WASP N-terminal domain and Btk in LPS-induced inflammatory response inmacrophages. PLoS One. 2012;7(1):e30351.
72. Jefferies CA, Doyle S, Brunner C, et al. Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4. J Biol Chem. 2003;278(28):26258-26264. (Pubitemid 36835395)
73. Gray P, Dunne A, Brikos C, Jefferies CA, Doyle SL, O'Neill LA. MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction. J Biol Chem. 2006;281(15):10489-10495. (Pubitemid 43864588)
74. Mansell A, Smith R, Doyle SL, et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling bymediatingMal degradation. Nat Immunol. 2006;7(2):148-155. (Pubitemid 43135880)
75. Piao W, Song C, Chen H, et al. Tyrosine phosphorylation ofMyD88 adapter-like (Mal) is critical for signal transduction and blocked in endotoxin tolerance. J Biol Chem. 2008;283(6):3109-3119.
76. Liu X, Zhan Z, Li D, et al. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol. 2011;12(5):416-424.
77. Doyle SL, Jefferies CA,O'Neill LA. Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NF-kappaB activation by lipopolysaccharide. J Biol Chem. 2005;280(25):23496- 23501. (Pubitemid 40884827)
78. Liljeroos M, Vuolteenaho R,Morath S,Hartung T,Hallman M,OjaniemiM. Bruton's tyrosine kinase together with PI 3-kinase are part of Toll-like receptor 2 multiprotein complex and mediate LTA induced Toll-like receptor 2 responses inmacrophages. Cell Signal. 2007;19(3):625-633. (Pubitemid 46107814)
79. Sakurai H, Suzuki S, Kawasaki N, et al. Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem. 2003;278(38):36916-36923. (Pubitemid 37140026)
80. Chen LF,Williams SA,Mu Y, et al.NF-kappaB RelA phosphorylation regulates RelA acetylation.Mol Cell Biol. 2005;25(18):7966-7975. (Pubitemid 41262991)
81. Yang EJ, Yoon JH, Chung KC. Bruton's tyrosine kinase phosphorylates cAMP-responsive elementbinding protein at serine 133 during neuronal differentiation in immortalized hippocampal progenitor cells. J Biol Chem. 2004;279(3):1827-1837. (Pubitemid 38084450)
82. Schmidt NW, Thieu VT, Mann BA, Ahyi AN, Kaplan MH. Bruton's tyrosine kinase is required for TLR-induced IL-10 production. J Immunol. 2006;177(10):7203-7210. (Pubitemid 44715089)
83. Olsson S, Sundler R. Different roles for non-receptor tyrosine kinases in arachidonate release induced by zymosan and Staphylococcus aureus inmacrophages. J Inflamm (Lond). 2006;3:8.
84. Ni Gabhann J, Spence S, Wynne C, et al. Defects in acute responses to TLR4 in Btk-deficient mice result in impaired dendritic cell-induced IFN-gamma production by natural killer cells. Clin Immunol. 2011;142(3):373-382.
85. Mukhopadhyay S, George A, Bal V, Ravindran B, Rath S. Bruton's tyrosine kinase deficiency in macrophages inhibits nitric oxide generation leading to enhancement of IL-12 induction. J Immunol. 1999;163(4):1786-1792. (Pubitemid 29382176)
86. Mukhopadhyay S, Mohanty M, Mangla A, et al. Macrophage effector functions controlled by Bruton's tyrosine kinase are more crucial than the cytokine balance of T cell responses for microfilarial clearance. J Immunol. 2002;168(6):2914-2921. (Pubitemid 34211671)
87. Mukhopadhyay S, Sahoo PK, George A, Bal V, Rath S, Ravindran B. Delayed clearance of filarial infection and enhancedTh1 immunity due to modulation ofmacrophageAPCfunctions in xidmice. J Immunol. 1999;163(2):875-883. (Pubitemid 29328097)
88. Vijayan V, Baumgart-Vogt E, Naidu S, Qian G, Immenschuh S. Bruton's tyrosine kinase is required for TLR-dependent heme oxygenase-1 gene activation via Nrf2 inmacrophages. J Immunol. 2011;187(2):817-827.
89. Zorn CN, Keck S, Hendriks RW, Leitges M, Freudenberg MA, Huber M. Bruton's tyrosine kinase is dispensable for the Toll-like receptor-mediated activation of mast cells. Cell Signal. 2009;21(1):79-86.
90. Marron TU, Rohr K, Martinez-Gallo M, Yu J, Cunningham-Rundles C. TLR signaling and effector functions are intact in XLA neutrophils. Clin Immunol. 2010;137(1):74-80.
91. Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients.Medicine (Baltimore). 2006;85(4):193-202. (Pubitemid 44107177)
92. Moore ML, McKissic EL, Brown CC, Wilkinson JE, Spindler KR. Fatal disseminated mouse adenovirus type 1 infection in mice lacking B cells or Bruton's tyrosine kinase. J Virol. 2004;78(11):5584-5590. (Pubitemid 38661645)
93. Sochorova K, Horvath R, Rozkova D, et al. Impaired Toll-like receptor 8-mediated IL-6 and TNFalpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia. Blood. 2007;109(6):2553-2556. (Pubitemid 46425901)
94. Taneichi H, Kanegane H, Sira MM, et al. Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia. Clin Immunol. 2008;126(2):148-154.
95. Lindvall JM, Blomberg KE, Valiaho J, et al. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev. 2005;203:200-215. (Pubitemid 40185385)
96. Frei R, Steinle J, Birchler T, et al.MHCclass II molecules enhance Toll-like receptor mediated innate immune responses. PLoS ONE. 2010;5(1):e8808.
97. KissnerTL, RuthelG,AlamS,UlrichRG,FernandezS, SaikhKU. ActivationofMyD88signalingupon staphylococcal enterotoxin binding to MHC class II molecules. PLoS One. 2011;6(1):e15985.
98. Ormsby T, Schlecker E, Ferdin J, et al. Btk is a positive regulator in the TREM-1/DAP12 signaling pathway. Blood. 2011;118(4):936-945.
99. MelcherM, Unger B, Schmidt U, Rajantie IA, Alitalo K, Ellmeier W. Essential roles for the Tec family kinases Tec and Btk in M-CSF receptor signaling pathways that regulate macrophage survival. J Immunol. 2008;180(12):8048-8056.
100. Ekman N, Lymboussaki A, Vastrik I, Sarvas K, Kaipainen A, Alitalo K. Bmx tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries. Circulation. 1997;96(6):1729-1732. (Pubitemid 27400725)
101. Semaan N, Alsaleh G, Gottenberg JE, Wachsmann D, Sibilia J. Etk/BMX, a Btk family tyrosine kinase, and Mal contribute to the cross-talk between MyD88 and FAK pathways. J Immunol. 2008;180(5):3485-3491.
102. Gottar-Guillier M, Dodeller F, Huesken D, et al. The tyrosine kinase BMX is an essential mediator of inflammatory arthritis in a kinase- independentmanner. J Immunol. 2011;186(10):6014-6023.
103. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol. 2009;5(10):531-541.
104. Senolt L, Vencovsky J, Pavelka K, Ospelt C, Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev. 2009;9(2):102-107.
105. Nishikawa M, Myoui A, Tomita T, Takahi K, Nampei A, Yoshikawa H. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum. 2003;48(9):2670-2681. (Pubitemid 37129445)
106. Zwerina J, Hayer S, Redlich K, et al. Activation of p38 MAPK is a key step in tumor necrosis factormediated inflammatory bone destruction. Arthritis Rheum. 2006;54(2):463-472. (Pubitemid 43228620)
107. Alten RE, Zerbini C, Jeka S, et al. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stablemethotrexate therapy. Ann Rheum Dis. 2010;69(2):364-367.
108. Cohen SB, Cheng TT, Chindalore V, et al. Evaluation of the efficacy and safety of pamapimod, a p38MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 2009;60(2):335-344.
109. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX- 702, a novel p38MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009;60(5):1232-1241.
110. GenoveseMC,Cohen SB,WofsyD, et al.A24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol. 2011;38(5):846-854.
111. Hammaker D, Firestein GS. "Go upstream, young man": lessons learned from the p38 saga. Ann Rheum Dis. 2010;69(Suppl. 1):i77-i82.
112. Pine PR, Chang B, Schoettler N, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol. 2007;124(3):244-257. (Pubitemid 47247604)
113. Jakus Z, Simon E, Balazs B, Mocsai A. Genetic deficiency of Syk protects mice from autoantibodyinduced arthritis. Arthritis Rheum. 2010;62(7):1899-1910.
114. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 2008;58(11):3309-3318.
115. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011;63(2):337-345.
116. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010;363(14):1303-1312.
117. Maeshima K, Yamaoka K, Kubo S, et al. A JAK inhibitor tofacitinib regulates synovitis through inhibition of IFN-gamma and IL-17 production by human CD4(+) T cells. Arthritis Rheum. 2011 doi: 10.1002/art.34329[Epub ahead of print].
118. Rosengren S, Corr M, Firestein GS, Boyle DL. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis. 2011 doi:10.1136/ard.2011.150284 [Epub ahead of print].
119. Garber K. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat Biotechnol. 2011;29(6):467-468.
120. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24(4):513-526.
121. Bonilla-HernanMG,Miranda-CarusME,Martin-Mola E. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology (Oxford). 2011;50(9):1542-1550.
122. Balachandran VP, CavnarMJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. NatMed. 2011;17(9):1094-1100.
123. Quintas-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond-exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol. 2009;6(9):535-543.
124. Terabe F, Kitano M, Kawai M, et al. Imatinib mesylate inhibited rat adjuvant arthritis and PDGFdependent growth of synovial fibroblast via interference with the Akt signaling pathway. Mod Rheumatol. 2009;19(5):522-529.
125. Koyama K, Hatsushika K, Ando T, et al. Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice.Mod Rheumatol. 2007;17(4):306-310. (Pubitemid 47263822)
126. Crespo O, Kang SC, Daneman R, et al. Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mousemodel ofmultiple sclerosis. J Clin Immunol. 2011;31(6):1010-1020.
127. Dehlin M, Andersson S, Erlandsson M, Brisslert M, Bokarewa M. Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation. J Leukoc Biol. 2011;90(4):811-817.
128. Louvet C, Szot GL, Lang J, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabeticmice. Proc Nat Acad Sci USA. 2008;105(48):18895-18900.
129. Weichsel R, Dix C,Wooldridge L, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008;14(8):2484-2491. (Pubitemid 351551084)
130. Das J, Chen P, Norris D, et al. 2-aminothiazole as a novel kinase inhibitor template. Structureactivity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2- hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. JMed Chem. 2006;49(23):6819-6832. (Pubitemid 44749749)
131. HantschelO, Rix U, SchmidtU, et al.TheBtk tyrosine kinase is amajor target of the Bcr-Abl inhibitor dasatinib. Proc Nat Acad Sci USA. 2007;104(33):13283-13288. (Pubitemid 47293937)
132. Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, Dibb NJ. Dasatinib is a potent inhibitor of tumour-associatedmacrophages, osteoclasts and the FMS receptor. Leukemia. 2009;23(3):590-594.
133. Di Paolo JA, Huang T, Balazs M, et al. Specific Btk inhibition suppresses B cell- and myeloid cellmediated arthritis. Nat Chem Biol. 2011;7(1):41-50.
134. Mahajan S,Ghosh S, Sudbeck EA, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem. 1999;274(14):9587-9599.
135. Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMed Chem. 2007;2(1):58-61.
136. Honigberg LA, Smith AM, Sirisawad M, et al.The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Nat Acad Sci USA. 2010;107(29):13075-13080.
137. Liu L, Di Paolo J, Barbosa J, Rong H, Reif K, Wong H. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/ pharmacodynamicmodeling: relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol ExpTher. 2011;338(1):154-163.
138. Chang BY, Huang MM, Francesco M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011;13(4):R115.
139. Huang Q, Pope RM. Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis. J Leukoc Biol. 2010;88(2):253-262.